This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Le Conte, P Articles by Drugeon, H B Search for Related Content PubMed PubMed Citation Articles by Le Conte, P Articles by Drugeon, H B

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1994 December; 38(12): 2695-2701

Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model.

P Le Conte, F Le Gallou, G Potel, L Struillou, D Baron and H B Drugeon

Laboratoire d'Antibiologie Clinique et Expérimentale, Faculté de Médecine, Nantes, France.

ABSTRACT

Capreomycin was incorporated into multilamellar vesicles of pure dipalmitoylphosphatidylcholine. The pharmacokinetics and nephrotoxicity of capreomycin in the free and liposomal forms were studied in normal mice. The efficacies of the two forms were evaluated by using the Mycobacterium avium complex beige mouse model. Approximately 10(7) viable M. avium cells were injected intravenously. Seven days later, treatment with either liposomal or free capreomycin at 60 or 120 mg/kg of body weight was administered daily for 5 days. Mice were sacrificed 5 days after the end of treatment, and the viable bacteria in liver, spleen, lungs, and blood were counted. After 5 days of treatment with dosages of 60 or 120 mg/kg/day, the level of blood urea nitrogen increased in the group treated with free capreomycin but not in the group treated with liposomal capreomycin. After intravenous injection of 120 mg/kg, liposomes enhanced the diffusion of capreomycin in the spleen, lungs, and kidneys and increased the half-life in serum. The 120-mg/kg dose of liposomal capreomycin significantly reduced the number of viable mycobacteria in the liver, spleen, and blood compared with those in the controls. Although these results are promising, further studies are needed to assess the efficacy of liposomal capreomycin for the treatment of M. avium complex infections.

---

Antimicrob Agents Chemother. 1994 December; 38(12): 2695-2701

This article has been cited by other articles:

• de Steenwinkel, J. E. M., van Vianen, W., ten Kate, M. T., Verbrugh, H. A., van Agtmael, M. A., Schiffelers, R. M., Bakker-Woudenberg, I. A. J. M. (2007). Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice. J Antimicrob Chemother 60: 1064-1073 [Abstract] [Full Text]  
• Garcia-Contreras, L., Fiegel, J., Telko, M. J., Elbert, K., Hawi, A., Thomas, M., VerBerkmoes, J., Germishuizen, W. A., Fourie, P. B., Hickey, A. J., Edwards, D. (2007). Inhaled Large Porous Particles of Capreomycin for Treatment of Tuberculosis in a Guinea Pig Model. Antimicrob. Agents Chemother. 51: 2830-2836 [Abstract] [Full Text]  
• Gaspar, M. M., Neves, S., Portaels, F., Pedrosa, J., Silva, M. T., Cruz, M. E. M. (2000). Therapeutic Efficacy of Liposomal Rifabutin in a Mycobacterium avium Model of Infection. Antimicrob. Agents Chemother. 44: 2424-2430 [Abstract] [Full Text]  
• Adams, L. B., Sinha, I., Franzblau, S. G., Krahenbuhl, J. L., Mehta, R. T. (1999). Effective Treatment of Acute and Chronic Murine Tuberculosis with Liposome-Encapsulated Clofazimine. Antimicrob. Agents Chemother. 43: 1638-1643 [Abstract] [Full Text]